Hyponatremia under MAP kinase inhibitors: a complex relationship between aquaporins and ERK activation
We read with interest the recent review by Workeneh et al.1 related to the epidemiologic and pathophysiological issues of hyponatremia in cancer. Our group recently reported data about hyponatremia under mitogen-activated protein kinase inhibitors in melanoma.2 We hypothesized that B-Raf (BRAF)/mitogen-activated protein kinase kinase inhibitors could activate aquaporin-2 trafficking in tubular epithelia from intracellular sites to the luminal membrane and discussed potential mechanisms underlying the complex relationship between aquaporins and extracellular signal–regulated kinase (ERK) activation.
Source: Kidney International - Category: Urology & Nephrology Authors: Florence Assan, Ziad A. Massy Tags: Letter to the Editor Source Type: research
More News: Cancer | Cancer & Oncology | Epidemiology | Melanoma | Skin Cancer | Urology & Nephrology